Trial Outcomes & Findings for Dose Ranging of GSK2336805 in Combination Therapy (NCT NCT01648140)

Last Updated: 2017-06-02

Results Overview

eRVR is defined as plasma HCV ribonucleic acid (RNA) \<lower limit of quantification (LLOQ) and target not detected at Weeks 4 and 12. Participants who discontinued prior to Week 12 assessments or had missing HCV RNA values at Weeks 4 and 12 were treated as non-responders.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

286 participants

Primary outcome timeframe

Week 4 and Week 12

Results posted on

2017-06-02

Participant Flow

This study was conducted across 29 centers in 6 countries (United States, Puerto Rico, Germany, Belgium, France, and Bulgaria) from 15 August 2012 to 16 July 2014.

Participants with treatment-naïve(TN) chronic genotype1(G1) hepatitis C virus (HCV) infection were randomly allocated on 2:2:1 basis to 2 dose levels of GSK2336805 or telaprevir. In a nonrandomized single-arm cohort, participants with TN genotype4(G4) chronic HCV infection were enrolled in parallel at dose level of 60 milligrams (mg) of GSK2336805.

Participant milestones

Participant milestones
Measure	GSK2336805 40 mg, G1 HCV Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (Pegylated Interferon Alfa-2a \[PEG\] + Ribavirin \[RIBA\]) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the extended rapid virologic response (eRVR) achievement. PEG dose was 180 micrograms (µg) once weekly subcutaneous (SC) injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kilogram \[kg\]) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, G1 HCV Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, G1 HCV Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, G4 HCV Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Overall Study STARTED	41	40	17	13
Overall Study COMPLETED	29	28	9	11
Overall Study NOT COMPLETED	12	12	8	2

Reasons for withdrawal

Reasons for withdrawal
Measure	GSK2336805 40 mg, G1 HCV Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (Pegylated Interferon Alfa-2a \[PEG\] + Ribavirin \[RIBA\]) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the extended rapid virologic response (eRVR) achievement. PEG dose was 180 micrograms (µg) once weekly subcutaneous (SC) injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kilogram \[kg\]) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, G1 HCV Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, G1 HCV Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, G4 HCV Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Overall Study Physician Decision	1	0	0	0
Overall Study Lack of Efficacy	4	7	1	0
Overall Study Adverse Event	3	1	2	0
Overall Study Withdrawal by Subject	2	3	3	2
Overall Study Lost to Follow-up	2	1	2	0

Baseline Characteristics

Dose Ranging of GSK2336805 in Combination Therapy

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	GSK2336805 40 mg, Genotype 1 HCV n=41 Participants Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, Genotype 1 HCV n=40 Participants Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, Genotype 1 HCV n=17 Participants Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, Genotype 4 HCV n=13 Participants Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Total n=111 Participants Total of all reporting groups
Age, Continuous	43.7 Years STANDARD_DEVIATION 13.23 • n=5 Participants	40.8 Years STANDARD_DEVIATION 9.87 • n=7 Participants	39.4 Years STANDARD_DEVIATION 12.02 • n=5 Participants	45.3 Years STANDARD_DEVIATION 11.46 • n=4 Participants	42.2 Years STANDARD_DEVIATION 11.73 • n=21 Participants
Sex: Female, Male Female	13 Participants n=5 Participants	16 Participants n=7 Participants	6 Participants n=5 Participants	3 Participants n=4 Participants	38 Participants n=21 Participants
Sex: Female, Male Male	28 Participants n=5 Participants	24 Participants n=7 Participants	11 Participants n=5 Participants	10 Participants n=4 Participants	73 Participants n=21 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants
Race (NIH/OMB) Black or African American	6 Participants n=5 Participants	6 Participants n=7 Participants	2 Participants n=5 Participants	3 Participants n=4 Participants	17 Participants n=21 Participants
Race (NIH/OMB) White	34 Participants n=5 Participants	33 Participants n=7 Participants	15 Participants n=5 Participants	9 Participants n=4 Participants	91 Participants n=21 Participants
Race (NIH/OMB) More than one race	1 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	2 Participants n=21 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants

PRIMARY outcome

Timeframe: Week 4 and Week 12

Population: Intent-To-Treat (ITT) Population: comprised of all participants who met the study criteria and were randomly assigned to treatment in the study with documented evidence of having received at least 1 dose of randomized treatment and at least 1 post Baseline HCV RNA measurement.

Outcome measures

Outcome measures
Measure	GSK2336805 40 mg, Genotype 1 HCV n=41 Participants Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, Genotype 1 HCV n=40 Participants Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, Genotype 1 HCV n=17 Participants Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, Genotype 4 HCV n=13 Participants Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Number of Participants Achieving eRVR	23 Participants	21 Participants	9 Participants	9 Participants

PRIMARY outcome

Timeframe: From the start of study treatment up to Week 12

Population: Safety Population: comprised of all participants who received at least 1 dose of study medication (GSK2336805 or telaprevir).

An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign(including an abnormal laboratory finding), symptom, or disease(new or exacerbated) temporally associated with the use of a medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, a congenital anomaly/birth defect, important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition.

Outcome measures

Outcome measures
Measure	GSK2336805 40 mg, Genotype 1 HCV n=41 Participants Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, Genotype 1 HCV n=40 Participants Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, Genotype 1 HCV n=17 Participants Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, Genotype 4 HCV n=13 Participants Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs) up to Week 12 Any AE	39 Participants	37 Participants	17 Participants	13 Participants
Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs) up to Week 12 Any SAE	0 Participants	2 Participants	3 Participants	1 Participants

PRIMARY outcome

Timeframe: Baseline (Week 0) up to 12-week treatment period

Population: Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.

Blood pressure measurements were taken to observe vital signs and included SBP and DBP at the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and Post-treatment (PT) Follow Up (FU) Weeks 4, 12 and 24. Change from Baseline in SBP and DBP is summarized for each post-Baseline assessment up to Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.

Outcome measures

Outcome measures
Measure	GSK2336805 40 mg, Genotype 1 HCV n=41 Participants Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, Genotype 1 HCV n=40 Participants Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, Genotype 1 HCV n=17 Participants Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, Genotype 4 HCV n=13 Participants Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points up to Week 12 SBP; Week1; n=41, 39, 15, 13	0.9 Millimeters of mercury (mmHg) Standard Deviation 12.99	-3 Millimeters of mercury (mmHg) Standard Deviation 11.24	-4.5 Millimeters of mercury (mmHg) Standard Deviation 12.67	-2.6 Millimeters of mercury (mmHg) Standard Deviation 11.84
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points up to Week 12 DBP; Day2; n=41, 40, 17, 13	-1.2 Millimeters of mercury (mmHg) Standard Deviation 6.63	-1 Millimeters of mercury (mmHg) Standard Deviation 7.03	-3 Millimeters of mercury (mmHg) Standard Deviation 9.03	-1.5 Millimeters of mercury (mmHg) Standard Deviation 10.45
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points up to Week 12 DBP; Week1; n=41, 39, 15, 13	-0.4 Millimeters of mercury (mmHg) Standard Deviation 7.98	-2.2 Millimeters of mercury (mmHg) Standard Deviation 9.13	1 Millimeters of mercury (mmHg) Standard Deviation 10.54	-1 Millimeters of mercury (mmHg) Standard Deviation 7.99
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points up to Week 12 DBP; Week2; n=41, 39, 14, 13	-0.4 Millimeters of mercury (mmHg) Standard Deviation 10.41	-1.7 Millimeters of mercury (mmHg) Standard Deviation 9.52	-0.3 Millimeters of mercury (mmHg) Standard Deviation 8.8	-2.8 Millimeters of mercury (mmHg) Standard Deviation 11.09
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points up to Week 12 DBP; Week4; n=41, 39, 14, 13	-1.2 Millimeters of mercury (mmHg) Standard Deviation 7.73	-4.4 Millimeters of mercury (mmHg) Standard Deviation 9.78	-3.9 Millimeters of mercury (mmHg) Standard Deviation 9.74	0.8 Millimeters of mercury (mmHg) Standard Deviation 9.92
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points up to Week 12 DBP; Week6; n=41, 39, 13, 13	-1.2 Millimeters of mercury (mmHg) Standard Deviation 7.65	-4.8 Millimeters of mercury (mmHg) Standard Deviation 9.86	-5.9 Millimeters of mercury (mmHg) Standard Deviation 7.82	-1.6 Millimeters of mercury (mmHg) Standard Deviation 10.1
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points up to Week 12 DBP; Week8; n=41, 39, 13, 13	-2.1 Millimeters of mercury (mmHg) Standard Deviation 10	-2.9 Millimeters of mercury (mmHg) Standard Deviation 9.11	-4.4 Millimeters of mercury (mmHg) Standard Deviation 7.63	-2.4 Millimeters of mercury (mmHg) Standard Deviation 9.02
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points up to Week 12 DBP; Week12; n=38, 35, 12, 13	0.3 Millimeters of mercury (mmHg) Standard Deviation 8.48	-4.4 Millimeters of mercury (mmHg) Standard Deviation 10.24	-3.5 Millimeters of mercury (mmHg) Standard Deviation 9.2	-1 Millimeters of mercury (mmHg) Standard Deviation 9.11
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points up to Week 12 SBP; Day2; n=41, 40, 17, 13	-1.4 Millimeters of mercury (mmHg) Standard Deviation 10.1	-0.8 Millimeters of mercury (mmHg) Standard Deviation 12.85	-3.3 Millimeters of mercury (mmHg) Standard Deviation 10.46	-1.3 Millimeters of mercury (mmHg) Standard Deviation 13.95
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points up to Week 12 SBP; Week2; n=41, 39, 14, 13	-2 Millimeters of mercury (mmHg) Standard Deviation 10.57	-0.7 Millimeters of mercury (mmHg) Standard Deviation 11.67	-4.1 Millimeters of mercury (mmHg) Standard Deviation 12.67	-4.2 Millimeters of mercury (mmHg) Standard Deviation 17.35
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points up to Week 12 SBP; Week4; n=41, 39, 14, 13	-3.6 Millimeters of mercury (mmHg) Standard Deviation 11.56	-4.2 Millimeters of mercury (mmHg) Standard Deviation 16.2	-3.8 Millimeters of mercury (mmHg) Standard Deviation 9.73	-5.2 Millimeters of mercury (mmHg) Standard Deviation 15.3
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points up to Week 12 SBP; Week6; n=41, 39, 13, 13	-0.4 Millimeters of mercury (mmHg) Standard Deviation 14.47	-3.8 Millimeters of mercury (mmHg) Standard Deviation 13.28	-5.9 Millimeters of mercury (mmHg) Standard Deviation 11.39	0.2 Millimeters of mercury (mmHg) Standard Deviation 14.47
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points up to Week 12 SBP; Week8; n=41, 39, 13, 13	-3.7 Millimeters of mercury (mmHg) Standard Deviation 12.15	-1.5 Millimeters of mercury (mmHg) Standard Deviation 12.64	-2.9 Millimeters of mercury (mmHg) Standard Deviation 10.36	-4.2 Millimeters of mercury (mmHg) Standard Deviation 12.95
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points up to Week 12 SBP; Week12; n=38, 35, 12, 13	-1.9 Millimeters of mercury (mmHg) Standard Deviation 13.65	-1.4 Millimeters of mercury (mmHg) Standard Deviation 11.72	-5.2 Millimeters of mercury (mmHg) Standard Deviation 5.81	-2.6 Millimeters of mercury (mmHg) Standard Deviation 19.16

PRIMARY outcome

Timeframe: Baseline (Week 0) and Day 2, Weeks 1, 2, 4, 6, 8, and 12

Vital sign monitoring included heart rate, measured at the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4, 12 and 24. Change from Baseline in heart rate is summarized for each post-Baseline assessment upto Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.

Outcome measures

Outcome measures
Measure	GSK2336805 40 mg, Genotype 1 HCV n=41 Participants Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, Genotype 1 HCV n=40 Participants Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, Genotype 1 HCV n=17 Participants Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, Genotype 4 HCV n=13 Participants Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Mean Change From Baseline in Heart Rate at the Indicated Time Points up to Week 12 Heart Rate; Day2; n=41, 40, 17, 13	6.5 Beats per minute Standard Deviation 8.65	5.4 Beats per minute Standard Deviation 9.96	9.3 Beats per minute Standard Deviation 11.74	3.8 Beats per minute Standard Deviation 5.79
Mean Change From Baseline in Heart Rate at the Indicated Time Points up to Week 12 Heart Rate; Week1; n=41, 39, 15, 13	1.5 Beats per minute Standard Deviation 8.33	3.1 Beats per minute Standard Deviation 8.75	8.1 Beats per minute Standard Deviation 6.32	7.7 Beats per minute Standard Deviation 10.11
Mean Change From Baseline in Heart Rate at the Indicated Time Points up to Week 12 Heart Rate; Week2; n=41, 39, 14, 13	3.8 Beats per minute Standard Deviation 9.02	4.2 Beats per minute Standard Deviation 12.14	8.7 Beats per minute Standard Deviation 8.17	7.8 Beats per minute Standard Deviation 8.6
Mean Change From Baseline in Heart Rate at the Indicated Time Points up to Week 12 Heart Rate; Week4; n=41, 39, 14, 13	6.8 Beats per minute Standard Deviation 9.42	4.2 Beats per minute Standard Deviation 11.78	10.7 Beats per minute Standard Deviation 11.39	5.5 Beats per minute Standard Deviation 8.35
Mean Change From Baseline in Heart Rate at the Indicated Time Points up to Week 12 Heart Rate; Week6; n=41, 39, 13, 13	8 Beats per minute Standard Deviation 10.15	5 Beats per minute Standard Deviation 10.98	13.8 Beats per minute Standard Deviation 9.75	10.2 Beats per minute Standard Deviation 8.2
Mean Change From Baseline in Heart Rate at the Indicated Time Points up to Week 12 Heart Rate; Week8; n=41, 39, 13, 13	4.7 Beats per minute Standard Deviation 9.91	6.8 Beats per minute Standard Deviation 12.42	14.2 Beats per minute Standard Deviation 10.36	12.8 Beats per minute Standard Deviation 12.27
Mean Change From Baseline in Heart Rate at the Indicated Time Points up to Week 12 Heart Rate; Week12; n=38, 35, 12, 13	7 Beats per minute Standard Deviation 9.2	5.3 Beats per minute Standard Deviation 12.1	11 Beats per minute Standard Deviation 8.02	8.4 Beats per minute Standard Deviation 9.47

PRIMARY outcome

Timeframe: Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12

Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count and white blood cell count at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the basophils, eosinophils, lymphocytes, total neutrophils, platelet count and white blood cell count values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.

Outcome measures

PRIMARY outcome

Timeframe: Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12

Blood samples were collected for the measurement of red blood cell count at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the red blood cell count values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.

Outcome measures

Outcome measures
Measure	GSK2336805 40 mg, Genotype 1 HCV n=41 Participants Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, Genotype 1 HCV n=40 Participants Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, Genotype 1 HCV n=17 Participants Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, Genotype 4 HCV n=13 Participants Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Mean Change From Baseline in Red Blood Cell Count at the Indicated Time Points up to Week 12 Red Blood Cell count; Week2; n=41, 38, 14, 12	-0.48 Trillion cells per liter Standard Deviation 0.376	-0.44 Trillion cells per liter Standard Deviation 0.508	-0.57 Trillion cells per liter Standard Deviation 0.312	-0.28 Trillion cells per liter Standard Deviation 0.361
Mean Change From Baseline in Red Blood Cell Count at the Indicated Time Points up to Week 12 Red Blood Cell count; Week1; n=38, 39, 14, 12	-0.15 Trillion cells per liter Standard Deviation 0.226	-0.04 Trillion cells per liter Standard Deviation 0.279	-0.18 Trillion cells per liter Standard Deviation 0.212	-0.13 Trillion cells per liter Standard Deviation 0.303
Mean Change From Baseline in Red Blood Cell Count at the Indicated Time Points up to Week 12 Red Blood Cell count; Week4; n=41, 38, 14, 13	-0.88 Trillion cells per liter Standard Deviation 0.507	-0.64 Trillion cells per liter Standard Deviation 0.623	-1.03 Trillion cells per liter Standard Deviation 0.441	-0.72 Trillion cells per liter Standard Deviation 0.559
Mean Change From Baseline in Red Blood Cell Count at the Indicated Time Points up to Week 12 Red Blood Cell count; Week6; n=41, 38, 12, 13	-0.97 Trillion cells per liter Standard Deviation 0.504	-0.78 Trillion cells per liter Standard Deviation 0.563	-1.28 Trillion cells per liter Standard Deviation 0.49	-0.86 Trillion cells per liter Standard Deviation 0.52
Mean Change From Baseline in Red Blood Cell Count at the Indicated Time Points up to Week 12 Red Blood Cell count; Week8; n=39, 39, 13, 13	-1.01 Trillion cells per liter Standard Deviation 0.506	-0.82 Trillion cells per liter Standard Deviation 0.534	-1.45 Trillion cells per liter Standard Deviation 0.357	-0.85 Trillion cells per liter Standard Deviation 0.412
Mean Change From Baseline in Red Blood Cell Count at the Indicated Time Points up to Week 12 Red Blood Cell count; Week12; n=38, 36, 12, 12	-1.08 Trillion cells per liter Standard Deviation 0.48	-0.79 Trillion cells per liter Standard Deviation 0.56	-1.61 Trillion cells per liter Standard Deviation 0.464	-0.92 Trillion cells per liter Standard Deviation 0.459

PRIMARY outcome

Timeframe: Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12

Blood samples were collected for the measurement of hemoglobin at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the hemoglobin values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.

Outcome measures

Outcome measures
Measure	GSK2336805 40 mg, Genotype 1 HCV n=41 Participants Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, Genotype 1 HCV n=40 Participants Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, Genotype 1 HCV n=17 Participants Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, Genotype 4 HCV n=13 Participants Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Mean Change From Baseline in Hemoglobin at the Indicated Time Points up to Week 12 Hemoglobin; Week1; n=38, 39, 14, 12	-5.2 Grams per liter Standard Deviation 6.98	-2.3 Grams per liter Standard Deviation 9.38	-6.6 Grams per liter Standard Deviation 5.83	-5.3 Grams per liter Standard Deviation 8.85
Mean Change From Baseline in Hemoglobin at the Indicated Time Points up to Week 12 Hemoglobin; Week2; n=41, 38, 14, 12	-16.7 Grams per liter Standard Deviation 12.54	-14.9 Grams per liter Standard Deviation 16.21	-20.5 Grams per liter Standard Deviation 10.66	-9.9 Grams per liter Standard Deviation 11.5
Mean Change From Baseline in Hemoglobin at the Indicated Time Points up to Week 12 Hemoglobin; Week4; n=41, 38, 14, 13	-28.6 Grams per liter Standard Deviation 15.38	-22.1 Grams per liter Standard Deviation 18.98	-34.4 Grams per liter Standard Deviation 13.55	-22.5 Grams per liter Standard Deviation 14.89
Mean Change From Baseline in Hemoglobin at the Indicated Time Points up to Week 12 Hemoglobin; Week6; n=41, 38, 12, 13	-30.1 Grams per liter Standard Deviation 14.54	-24.7 Grams per liter Standard Deviation 16	-40.8 Grams per liter Standard Deviation 14.11	-25.2 Grams per liter Standard Deviation 12.28
Mean Change From Baseline in Hemoglobin at the Indicated Time Points up to Week 12 Hemoglobin; Week8; n=39, 39, 13, 13	-30.5 Grams per liter Standard Deviation 13.29	-25.5 Grams per liter Standard Deviation 14.22	-44.9 Grams per liter Standard Deviation 11.73	-25.2 Grams per liter Standard Deviation 8.66
Mean Change From Baseline in Hemoglobin at the Indicated Time Points up to Week 12 Hemoglobin; Week12; n=38, 36, 12, 12	-33 Grams per liter Standard Deviation 12.88	-24.1 Grams per liter Standard Deviation 13.41	-47.4 Grams per liter Standard Deviation 14.12	-27.6 Grams per liter Standard Deviation 12.05

PRIMARY outcome

Timeframe: Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12

Blood samples were collected for the measurement of hematocrit at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the hematocrit values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.

Outcome measures

Outcome measures
Measure	GSK2336805 40 mg, Genotype 1 HCV n=41 Participants Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, Genotype 1 HCV n=40 Participants Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, Genotype 1 HCV n=17 Participants Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, Genotype 4 HCV n=13 Participants Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Mean Change From Baseline in Hematocrit at the Indicated Time Points up to Week 12 Hematocrit; Week1; n=38, 39, 14, 12	-0.0196 Ratio Standard Deviation 0.02345	-0.0069 Ratio Standard Deviation 0.02751	-0.0201 Ratio Standard Deviation 0.01921	-0.0166 Ratio Standard Deviation 0.0298
Mean Change From Baseline in Hematocrit at the Indicated Time Points up to Week 12 Hematocrit; Week2; n=41, 38, 14, 12	-0.0539 Ratio Standard Deviation 0.03653	-0.0465 Ratio Standard Deviation 0.04738	-0.0609 Ratio Standard Deviation 0.03007	-0.0335 Ratio Standard Deviation 0.03625
Mean Change From Baseline in Hematocrit at the Indicated Time Points up to Week 12 Hematocrit; Week4; n=41, 38, 14, 13	-0.0848 Ratio Standard Deviation 0.04576	-0.0621 Ratio Standard Deviation 0.05468	-0.0999 Ratio Standard Deviation 0.03967	-0.0668 Ratio Standard Deviation 0.04445
Mean Change From Baseline in Hematocrit at the Indicated Time Points up to Week 12 Hematocrit; Week6; n=41, 38, 12, 13	-0.0859 Ratio Standard Deviation 0.0411	-0.0685 Ratio Standard Deviation 0.04487	-0.1203 Ratio Standard Deviation 0.04463	-0.074 Ratio Standard Deviation 0.03316
Mean Change From Baseline in Hematocrit at the Indicated Time Points up to Week 12 Hematocrit; Week8; n=39, 39, 13, 13	-0.0838 Ratio Standard Deviation 0.03955	-0.0663 Ratio Standard Deviation 0.04144	-0.1235 Ratio Standard Deviation 0.03288	-0.07 Ratio Standard Deviation 0.02758
Mean Change From Baseline in Hematocrit at the Indicated Time Points up to Week 12 Hematocrit; Week12; n=38, 36, 12, 12	-0.0843 Ratio Standard Deviation 0.04038	-0.0589 Ratio Standard Deviation 0.03648	-0.1318 Ratio Standard Deviation 0.03847	-0.0688 Ratio Standard Deviation 0.03298

PRIMARY outcome

Timeframe: Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12

Blood samples were collected for the measurement of mean corpuscle volume at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the mean corpuscle volume values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.

Outcome measures

Outcome measures
Measure	GSK2336805 40 mg, Genotype 1 HCV n=41 Participants Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, Genotype 1 HCV n=40 Participants Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, Genotype 1 HCV n=17 Participants Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, Genotype 4 HCV n=13 Participants Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Mean Change From Baseline in Mean Corpuscle Volume at the Indicated Time Points up to Week 12 Mean corpuscle volume; Week8; n=39, 39, 13, 13	3.8 Femtoliters Standard Deviation 5.39	3 Femtoliters Standard Deviation 5.2	3.1 Femtoliters Standard Deviation 2.78	2.2 Femtoliters Standard Deviation 3.75
Mean Change From Baseline in Mean Corpuscle Volume at the Indicated Time Points up to Week 12 Mean corpuscle volume; Week1; n=38, 39, 14, 12	-1.1 Femtoliters Standard Deviation 1.21	-0.8 Femtoliters Standard Deviation 1.37	-0.4 Femtoliters Standard Deviation 1.15	-0.7 Femtoliters Standard Deviation 1.37
Mean Change From Baseline in Mean Corpuscle Volume at the Indicated Time Points up to Week 12 Mean corpuscle volume; Week2; n=41, 38, 14, 12	-2 Femtoliters Standard Deviation 1.84	-1.4 Femtoliters Standard Deviation 1.59	-1.4 Femtoliters Standard Deviation 1.09	-1.5 Femtoliters Standard Deviation 1.45
Mean Change From Baseline in Mean Corpuscle Volume at the Indicated Time Points up to Week 12 Mean corpuscle volume; Week4; n=41, 38, 14, 13	0.3 Femtoliters Standard Deviation 3.33	0.2 Femtoliters Standard Deviation 3.4	-0.8 Femtoliters Standard Deviation 1.58	-0.2 Femtoliters Standard Deviation 2.94
Mean Change From Baseline in Mean Corpuscle Volume at the Indicated Time Points up to Week 12 Mean corpuscle volume; Week6; n=41, 38, 12, 13	2.3 Femtoliters Standard Deviation 4.76	1.8 Femtoliters Standard Deviation 4.67	-0.2 Femtoliters Standard Deviation 2.37	1.4 Femtoliters Standard Deviation 4.63
Mean Change From Baseline in Mean Corpuscle Volume at the Indicated Time Points up to Week 12 Mean corpuscle volume; Week12; n=38, 34, 12, 12	5.7 Femtoliters Standard Deviation 6	4.2 Femtoliters Standard Deviation 6.3	5.3 Femtoliters Standard Deviation 4.14	3.8 Femtoliters Standard Deviation 4.28

PRIMARY outcome

Timeframe: Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12

Blood samples were collected for the measurement of albumin at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the albumin values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.

Outcome measures

Outcome measures
Measure	GSK2336805 40 mg, Genotype 1 HCV n=41 Participants Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, Genotype 1 HCV n=40 Participants Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, Genotype 1 HCV n=17 Participants Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, Genotype 4 HCV n=13 Participants Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Mean Change From Baseline in Albumin at the Indicated Time Points up to Week 12 Albumin; Week1; n=40, 39, 15, 13	-0.6 Grams per liter Standard Deviation 2.67	-0.3 Grams per liter Standard Deviation 2.46	-1.1 Grams per liter Standard Deviation 1.6	-1 Grams per liter Standard Deviation 1.87
Mean Change From Baseline in Albumin at the Indicated Time Points up to Week 12 Albumin; Week2; n=41, 38, 14, 13	-1.3 Grams per liter Standard Deviation 2.98	-1.5 Grams per liter Standard Deviation 2.68	-2 Grams per liter Standard Deviation 2.6	-0.2 Grams per liter Standard Deviation 2.39
Mean Change From Baseline in Albumin at the Indicated Time Points up to Week 12 Albumin; Week4; n=41, 39, 14, 13	-1.9 Grams per liter Standard Deviation 2.48	-1.5 Grams per liter Standard Deviation 2.52	-3 Grams per liter Standard Deviation 3.21	-1.2 Grams per liter Standard Deviation 1.46
Mean Change From Baseline in Albumin at the Indicated Time Points up to Week 12 Albumin; Week6; n=41, 38, 13, 13	-2.2 Grams per liter Standard Deviation 2.65	-1.5 Grams per liter Standard Deviation 2.27	-3.5 Grams per liter Standard Deviation 3.36	-2.1 Grams per liter Standard Deviation 2.22
Mean Change From Baseline in Albumin at the Indicated Time Points up to Week 12 Albumin; Week8; n=40, 39, 13, 13	-2.6 Grams per liter Standard Deviation 2.99	-1.7 Grams per liter Standard Deviation 2	-3.7 Grams per liter Standard Deviation 4.71	-1.5 Grams per liter Standard Deviation 1.94
Mean Change From Baseline in Albumin at the Indicated Time Points up to Week 12 Albumin; Week12; n=37, 35, 12, 13	-2.1 Grams per liter Standard Deviation 3.03	-1.3 Grams per liter Standard Deviation 2.84	-3.3 Grams per liter Standard Deviation 3.02	-1.6 Grams per liter Standard Deviation 2.1

PRIMARY outcome

Timeframe: Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12

Blood samples were collected for the measurement of ALP, ALT, AST, CK and GGT at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4 Change from Baseline in the ALP, ALT, AST, CK and GGT values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.

Outcome measures

PRIMARY outcome

Timeframe: Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12

Blood samples were collected for the measurement of direct bilirubin, total bilirubin and creatinine at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the direct bilirubin, total bilirubin and creatinine values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.

Outcome measures

PRIMARY outcome

Timeframe: Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12

Blood samples were collected for the measurement of Chloride, bicarbonate, glucose, potassium, sodium, inorganic phosphorus and urea/BUN at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the chloride, bicarbonate, glucose, potassium, sodium, inorganic phosphorus and urea/BUN values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.

Outcome measures

PRIMARY outcome

Timeframe: Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12

Blood samples were collected for the measurement of Creatinine Clearance at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. It is estimated by Cockcroft-Gault Equation. Change from Baseline in the Creatinine Clearance values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.

Outcome measures

Outcome measures
Measure	GSK2336805 40 mg, Genotype 1 HCV n=41 Participants Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, Genotype 1 HCV n=40 Participants Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, Genotype 1 HCV n=17 Participants Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, Genotype 4 HCV n=13 Participants Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Mean Change From Baseline in Creatinine Clearance at the Indicated Time Points up to Week 12 Creatinine Clearance; Week1; n=40, 39, 15, 13	1.5 Milliliter per minute (mL/min) Standard Deviation 9.79	-2.1 Milliliter per minute (mL/min) Standard Deviation 19.51	-9.5 Milliliter per minute (mL/min) Standard Deviation 10.09	5.7 Milliliter per minute (mL/min) Standard Deviation 10.18
Mean Change From Baseline in Creatinine Clearance at the Indicated Time Points up to Week 12 Creatinine Clearance; Week2; n=41, 38,14,13	3.3 Milliliter per minute (mL/min) Standard Deviation 13.48	4.7 Milliliter per minute (mL/min) Standard Deviation 11.33	-9 Milliliter per minute (mL/min) Standard Deviation 12.55	-1.8 Milliliter per minute (mL/min) Standard Deviation 15.27
Mean Change From Baseline in Creatinine Clearance at the Indicated Time Points up to Week 12 Creatinine Clearance; Week4; n=41, 39,14,13	5 Milliliter per minute (mL/min) Standard Deviation 12.45	1.9 Milliliter per minute (mL/min) Standard Deviation 14.72	-9.1 Milliliter per minute (mL/min) Standard Deviation 13.42	4.5 Milliliter per minute (mL/min) Standard Deviation 16.19
Mean Change From Baseline in Creatinine Clearance at the Indicated Time Points up to Week 12 Creatinine Clearance; Week6; n=41, 38,13,13	2.7 Milliliter per minute (mL/min) Standard Deviation 11.93	-0.7 Milliliter per minute (mL/min) Standard Deviation 16.25	-19.1 Milliliter per minute (mL/min) Standard Deviation 20.54	1.5 Milliliter per minute (mL/min) Standard Deviation 13.12
Mean Change From Baseline in Creatinine Clearance at the Indicated Time Points up to Week 12 Creatinine Clearance; Week8; n=40, 39,13,13	1.9 Milliliter per minute (mL/min) Standard Deviation 10.49	3.4 Milliliter per minute (mL/min) Standard Deviation 19.94	-17.8 Milliliter per minute (mL/min) Standard Deviation 16.1	-3 Milliliter per minute (mL/min) Standard Deviation 14.54
Mean Change From Baseline in Creatinine Clearance at the Indicated Time Points up to Week 12 Creatinine Clearance; Week12; n=38,35,12,13	-0.2 Milliliter per minute (mL/min) Standard Deviation 15.06	2.2 Milliliter per minute (mL/min) Standard Deviation 17.27	-14.3 Milliliter per minute (mL/min) Standard Deviation 16.99	1.2 Milliliter per minute (mL/min) Standard Deviation 20.49

PRIMARY outcome

Timeframe: Baseline (Week 0), Weeks 2 and 12

Urine samples were collected for urinalysis at Baseline, Weeks 2, 12, 18, 24, 48 and PT FU Weeks 4. Number of participants with shift from Baseline in urinalysis to normal (NL), abnormal (ANL) and missing (MIS) data up to Week 12 are summarized. Urine bilirubin (UBIL), urine glucose (UGLU), urine ketones (UKET), urine leukocyte esterase test (ULET) for detecting WBC, urine nitrite (UNIT), urine occult blood (UOB) were performed with dipstick method. Urine microscopy (UM) is performed to detect bacteria (BAC), red blood cells (RBC) and white blood cells (WBC). Other urinalysis parameter included urine pH (UpH) and urine specific gravity (USG). Baseline value is defined as the last Pre-treatment value observed.

Outcome measures

Outcome measures
Measure	GSK2336805 40 mg, Genotype 1 HCV n=41 Participants Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, Genotype 1 HCV n=40 Participants Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, Genotype 1 HCV n=17 Participants Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, Genotype 4 HCV n=13 Participants Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12 Week 12, ULET, BL MIS to PBL MIS,n=37,34,12,13	37 Participants	34 Participants	12 Participants	13 Participants
Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12 Week 12, UMBT, BL MIS to PBL MIS,n=1,1,0,0	1 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12 Week 12, UMRBC, BL MIS to PBL MIS,n=4,5,2,2	4 Participants	5 Participants	2 Participants	2 Participants
Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12 Week 12, UNIT, BL MIS to PBL MIS,n=37,34,12,13	37 Participants	34 Participants	12 Participants	13 Participants
Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12 Week 12, UOB, BL MIS to PBL MIS,n=37,34,12,13	37 Participants	34 Participants	12 Participants	13 Participants
Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12 Week 2, UPH, BL NL to PBL NL, n=1, 0,0,0	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12 Week 12, UPH, BL NL to PBL NL, n=37,34,12,13	36 Participants	34 Participants	12 Participants	13 Participants
Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12 Week 2, USG, BL NL to PBL NL, n=1, 0,0,0	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12 Week 12, USG, BL NL to PBL NL, n=37,34,12,13	37 Participants	34 Participants	12 Participants	12 Participants
Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12 Week 2, UBIL, BL MIS to PBL MIS, n=1,0,0,0	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12 Week 12, UBIL, BL MIS to PBL MIS,n=37,34,12,13	37 Participants	34 Participants	12 Participants	13 Participants
Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12 Week 2, UGLU, BL MIS to PBL MIS, n=1,0,0,0	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12 Week 12, UGLU, BL MIS to PBL MIS,n=37,34,12,13	37 Participants	34 Participants	12 Participants	13 Participants
Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12 Week 2, UKET, BL MIS to PBL MIS, n=1,0,0,0	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12 Week 12, UKET, BL MIS to PBL MIS,n=37,34,12,13	37 Participants	34 Participants	12 Participants	13 Participants
Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12 Week 2, ULET, BL MIS to PBL MIS, n=1,0,0,0	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12 Week 12, UMWBC, BL MIS to PBL MIS, n=4,5,2,2	4 Participants	5 Participants	2 Participants	2 Participants
Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12 Week 2, UNIT, BL MIS to PBL MIS, n=1,0,0,0	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12 Week 2, UOB, BL MIS to PBL MIS, n=1,0,0,0	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12 Week 12, UPH, BL NL to PBL ANL, n=37,34,12,13	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12 Week 12, USG, BL NL to PBL ANL,n=37,34,12,13	0 Participants	0 Participants	0 Participants	1 Participants

PRIMARY outcome

Timeframe: Baseline (Week 0) and Weeks 1 and 12

The ECG parameter heart rate was measured at Baseline, Weeks 1 and 12. Change from Baseline in ECG heart rate is summarized for each post-Baseline assessment up to Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.

Outcome measures

Outcome measures
Measure	GSK2336805 40 mg, Genotype 1 HCV n=41 Participants Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, Genotype 1 HCV n=40 Participants Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, Genotype 1 HCV n=17 Participants Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, Genotype 4 HCV n=13 Participants Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Mean Change From Baseline in Electrocardiographic (ECG) Heart Rate Values at the Indicated Time Points up to Week 12 Week 1, n=41, 40, 15, 12	3.3 Beats per minute Standard Deviation 8.28	0.8 Beats per minute Standard Deviation 8.49	4.1 Beats per minute Standard Deviation 9.52	4.8 Beats per minute Standard Deviation 10.62
Mean Change From Baseline in Electrocardiographic (ECG) Heart Rate Values at the Indicated Time Points up to Week 12 Week 12, n=38, 35, 12, 13	8.3 Beats per minute Standard Deviation 8.37	5.1 Beats per minute Standard Deviation 10.86	9.3 Beats per minute Standard Deviation 10.15	8.5 Beats per minute Standard Deviation 8

PRIMARY outcome

Timeframe: Baseline (Week 0) and Weeks 1 and 12

The ECG parameters including PR interval, QRS duration, uncorrected QT interval, QTcB, QTcF were measured at Baseline, Weeks 1 and 12. Change from Baseline in ECG parameters are summarized for each post-Baseline assessment up to Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.

Outcome measures

Outcome measures
Measure	GSK2336805 40 mg, Genotype 1 HCV n=41 Participants Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, Genotype 1 HCV n=40 Participants Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, Genotype 1 HCV n=17 Participants Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, Genotype 4 HCV n=13 Participants Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Mean Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval and QT Interval Corrected Bazett's Formula (QTcB), QT Interval Corrected Using Fridericia's Formula (QTcF) Values at the Indicated Time Points up to Week 12 QTcF interval, Week 12,n=38,35,12,13	3.3516 Milliseconds Standard Deviation 26.34546	-3.1442 Milliseconds Standard Deviation 17.38368	1.6147 Milliseconds Standard Deviation 18.38188	10.7637 Milliseconds Standard Deviation 17.07259
Mean Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval and QT Interval Corrected Bazett's Formula (QTcB), QT Interval Corrected Using Fridericia's Formula (QTcF) Values at the Indicated Time Points up to Week 12 PR interval, Week 1, n=41, 40, 15, 12	0.5 Milliseconds Standard Deviation 19.43	1.2 Milliseconds Standard Deviation 13.57	2.7 Milliseconds Standard Deviation 7.27	-1.6 Milliseconds Standard Deviation 20.92
Mean Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval and QT Interval Corrected Bazett's Formula (QTcB), QT Interval Corrected Using Fridericia's Formula (QTcF) Values at the Indicated Time Points up to Week 12 PR interval, Week 12, n=38, 35, 12, 13	2.9 Milliseconds Standard Deviation 13.36	3.2 Milliseconds Standard Deviation 12.07	5.5 Milliseconds Standard Deviation 8.73	0.2 Milliseconds Standard Deviation 14.68
Mean Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval and QT Interval Corrected Bazett's Formula (QTcB), QT Interval Corrected Using Fridericia's Formula (QTcF) Values at the Indicated Time Points up to Week 12 QRS duration, Week 1, n=41, 40, 15,12	-6.6 Milliseconds Standard Deviation 50.28	0.4 Milliseconds Standard Deviation 7.69	2.9 Milliseconds Standard Deviation 6.61	0.4 Milliseconds Standard Deviation 4.03
Mean Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval and QT Interval Corrected Bazett's Formula (QTcB), QT Interval Corrected Using Fridericia's Formula (QTcF) Values at the Indicated Time Points up to Week 12 QRS duration, Week 12, n=38, 35, 12,13	-8.2 Milliseconds Standard Deviation 51.69	-1.8 Milliseconds Standard Deviation 6.44	0.4 Milliseconds Standard Deviation 7.54	-2 Milliseconds Standard Deviation 4.4
Mean Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval and QT Interval Corrected Bazett's Formula (QTcB), QT Interval Corrected Using Fridericia's Formula (QTcF) Values at the Indicated Time Points up to Week 12 Uncorrected QT Interval, Week 1, n=41,40,15,12	-2.3 Milliseconds Standard Deviation 27.29	-2.6 Milliseconds Standard Deviation 22.29	-2.1 Milliseconds Standard Deviation 22.39	5.9 Milliseconds Standard Deviation 25.68
Mean Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval and QT Interval Corrected Bazett's Formula (QTcB), QT Interval Corrected Using Fridericia's Formula (QTcF) Values at the Indicated Time Points up to Week 12 Uncorrected QT interval, Week 12,n=38,35,12,13	-11.8 Milliseconds Standard Deviation 31.28	-12 Milliseconds Standard Deviation 25.22	-17 Milliseconds Standard Deviation 18.01	-4.6 Milliseconds Standard Deviation 23.36
Mean Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval and QT Interval Corrected Bazett's Formula (QTcB), QT Interval Corrected Using Fridericia's Formula (QTcF) Values at the Indicated Time Points up to Week 12 QTcB interval, Week 1, n=41,40,15,12	7.7087 Milliseconds Standard Deviation 25.63001	0.2491 Milliseconds Standard Deviation 22.90285	9.8112 Milliseconds Standard Deviation 20.6771	19.8879 Milliseconds Standard Deviation 40.13504
Mean Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval and QT Interval Corrected Bazett's Formula (QTcB), QT Interval Corrected Using Fridericia's Formula (QTcF) Values at the Indicated Time Points up to Week 12 QTcB interval, Week 12,n=38,35,12,13	11.5512 Milliseconds Standard Deviation 26.5644	1.7615 Milliseconds Standard Deviation 20.3859	11.2801 Milliseconds Standard Deviation 25.54652	18.9943 Milliseconds Standard Deviation 16.76576
Mean Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval and QT Interval Corrected Bazett's Formula (QTcB), QT Interval Corrected Using Fridericia's Formula (QTcF) Values at the Indicated Time Points up to Week 12 QTcF interval, Week 1, n=41,40,15,12	4.1995 Milliseconds Standard Deviation 23.18239	-0.7151 Milliseconds Standard Deviation 19.69091	5.7676 Milliseconds Standard Deviation 17.06472	14.9187 Milliseconds Standard Deviation 32.2737

SECONDARY outcome

Timeframe: From Week 12 up to PT Week 24 FU

Population: Safety Population

An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign(including an abnormal laboratory finding), symptom, or disease(new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, a congenital anomaly/birth defect, important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition.

Outcome measures

Outcome measures
Measure	GSK2336805 40 mg, Genotype 1 HCV n=41 Participants Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, Genotype 1 HCV n=40 Participants Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, Genotype 1 HCV n=17 Participants Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, Genotype 4 HCV n=13 Participants Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Number of Participants With Any AEs and Any SAEs After Week 12 Any AE	21 Participants	22 Participants	8 Participants	9 Participants
Number of Participants With Any AEs and Any SAEs After Week 12 Any SAE	2 Participants	1 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: From the start of the treatment up to PT FU Week 24

Population: ITT Population

Blood samples for the determination of HCV RNA levels were collected at Screening and Baseline, every study visit during the Treatment Period, and at PT FU Weeks 4, 12, and 24. vRVR is defined as plasma HCV RNA \<LLOQ and target not detected 2 weeks after initiation of therapy. RVR is defined as plasma HCV RNA \<LLOQ and target not detected 4 weeks after initiation of therapy. cEVR is defined as plasma HCV RNA \<LLOQ and target not detected 12 weeks after initiation of therapy. SVR12 is defined as plasma HCV RNA \<LLOQ and target not detected 12 weeks after completion of all therapy. SVR24 is defined as plasma HCV RNA \<LLOQ and target not detected 24 weeks after completion of all therapy. SVR24 with RGT are participants who achieved both SVR24 and eRVR.

Outcome measures

Outcome measures
Measure	GSK2336805 40 mg, Genotype 1 HCV n=41 Participants Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, Genotype 1 HCV n=40 Participants Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, Genotype 1 HCV n=17 Participants Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, Genotype 4 HCV n=13 Participants Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Number of Participants Achieving Very Rapid Virologic Response (vRVR), Rapid Virologic Response (RVR), Complete Early Virologic Response (cEVR), Sustained Virologic Response 12 and 24 (SVR12 and SVR24) With Response Guided Treatment (RGT) cEVR	33 Participants	30 Participants	11 Participants	13 Participants
Number of Participants Achieving Very Rapid Virologic Response (vRVR), Rapid Virologic Response (RVR), Complete Early Virologic Response (cEVR), Sustained Virologic Response 12 and 24 (SVR12 and SVR24) With Response Guided Treatment (RGT) vRVR	8 Participants	12 Participants	8 Participants	6 Participants
Number of Participants Achieving Very Rapid Virologic Response (vRVR), Rapid Virologic Response (RVR), Complete Early Virologic Response (cEVR), Sustained Virologic Response 12 and 24 (SVR12 and SVR24) With Response Guided Treatment (RGT) RVR	23 Participants	23 Participants	10 Participants	9 Participants
Number of Participants Achieving Very Rapid Virologic Response (vRVR), Rapid Virologic Response (RVR), Complete Early Virologic Response (cEVR), Sustained Virologic Response 12 and 24 (SVR12 and SVR24) With Response Guided Treatment (RGT) SVR12	30 Participants	26 Participants	10 Participants	0 Participants
Number of Participants Achieving Very Rapid Virologic Response (vRVR), Rapid Virologic Response (RVR), Complete Early Virologic Response (cEVR), Sustained Virologic Response 12 and 24 (SVR12 and SVR24) With Response Guided Treatment (RGT) SVR24	27 Participants	25 Participants	10 Participants	0 Participants
Number of Participants Achieving Very Rapid Virologic Response (vRVR), Rapid Virologic Response (RVR), Complete Early Virologic Response (cEVR), Sustained Virologic Response 12 and 24 (SVR12 and SVR24) With Response Guided Treatment (RGT) SVR24 with RGT	17 Participants	17 Participants	9 Participants	0 Participants

SECONDARY outcome

Timeframe: Day 1, Day 2, Week 4, and Week 12

Population: PK Population included all participants who received GSK2336805 and underwent plasma PK sampling (intensive or sparse) during the study. Only participants for whom plasma PK samples were obtained were assessed (represented by n=X, X in category titles).

Plasma pharmacokinetic (PK) samples were collected for all participants on Day 1 (0 hour \[h\]-1h, 1h-4h, 4h-8h, 8h-20h), Day 2 (Predose \[20-28h\]), Week 4 (Predose \[20-28h\], 0h-1h, 1h-4h, 4h-8h, 8h-20h, 20h-28h) and Week 12 (Predose \[20-28h\]). PK Population is comprised of all participants who received GSK2336805 and underwent plasma PK sampling (intensive or sparse) during the study.

Outcome measures

Outcome measures
Measure	GSK2336805 40 mg, Genotype 1 HCV n=41 Participants Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, Genotype 1 HCV n=53 Participants Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, Genotype 1 HCV Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, Genotype 4 HCV Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Mean GSK2336805 Plasma Concentrations on Day 1, Day 2, Week 4, and Week 12 Week 4 (1h-4h), n=46, 52	392.78 nanograms per milliliter (ng/mL) Standard Deviation 275.504	591.07 nanograms per milliliter (ng/mL) Standard Deviation 402.442	—	—
Mean GSK2336805 Plasma Concentrations on Day 1, Day 2, Week 4, and Week 12 Day 1 (0h-1h), n=1, 3	NA nanograms per milliliter (ng/mL) Standard Deviation NA A value of NA indicates not applicable	604 nanograms per milliliter (ng/mL) Standard Deviation 392.763	—	—
Mean GSK2336805 Plasma Concentrations on Day 1, Day 2, Week 4, and Week 12 Day 1 (1h-4h), n=35, 42	290.39 nanograms per milliliter (ng/mL) Standard Deviation 241.05	445.18 nanograms per milliliter (ng/mL) Standard Deviation 314.624	—	—
Mean GSK2336805 Plasma Concentrations on Day 1, Day 2, Week 4, and Week 12 Day 1 (4h-8h), n=0, 3	NA nanograms per milliliter (ng/mL) Standard Deviation NA The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).	221.33 nanograms per milliliter (ng/mL) Standard Deviation 191.996	—	—
Mean GSK2336805 Plasma Concentrations on Day 1, Day 2, Week 4, and Week 12 Day 1 (8h-20h), n=0, 1	NA nanograms per milliliter (ng/mL) Standard Deviation NA The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).	NA nanograms per milliliter (ng/mL) Standard Deviation NA The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).	—	—
Mean GSK2336805 Plasma Concentrations on Day 1, Day 2, Week 4, and Week 12 Day 2 Predose (20-28h), n=36, 43	53.79 nanograms per milliliter (ng/mL) Standard Deviation 52.629	123.89 nanograms per milliliter (ng/mL) Standard Deviation 257.575	—	—
Mean GSK2336805 Plasma Concentrations on Day 1, Day 2, Week 4, and Week 12 Week 4 Predose (20-28h), n=33, 42	81.18 nanograms per milliliter (ng/mL) Standard Deviation 153.462	146.85 nanograms per milliliter (ng/mL) Standard Deviation 243.331	—	—
Mean GSK2336805 Plasma Concentrations on Day 1, Day 2, Week 4, and Week 12 Week 4 (0h-1h), n=2, 6	198.4 nanograms per milliliter (ng/mL) Standard Deviation 242.679	553 nanograms per milliliter (ng/mL) Standard Deviation 536.451	—	—
Mean GSK2336805 Plasma Concentrations on Day 1, Day 2, Week 4, and Week 12 Week 4 (4h-8h), n=22, 19	215.55 nanograms per milliliter (ng/mL) Standard Deviation 127.737	411.68 nanograms per milliliter (ng/mL) Standard Deviation 251.604	—	—
Mean GSK2336805 Plasma Concentrations on Day 1, Day 2, Week 4, and Week 12 Week 4 (8h-20h), n=1, 2	NA nanograms per milliliter (ng/mL) Standard Deviation NA The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).	192.5 nanograms per milliliter (ng/mL) Standard Deviation 94.045	—	—
Mean GSK2336805 Plasma Concentrations on Day 1, Day 2, Week 4, and Week 12 Week 4 (20h-28h), n=11, 10	51.24 nanograms per milliliter (ng/mL) Standard Deviation 57.261	66.29 nanograms per milliliter (ng/mL) Standard Deviation 53.604	—	—
Mean GSK2336805 Plasma Concentrations on Day 1, Day 2, Week 4, and Week 12 Week 12 (Predose [20-28h]), n=26, 35	45.99 nanograms per milliliter (ng/mL) Standard Deviation 42.034	142.59 nanograms per milliliter (ng/mL) Standard Deviation 178.252	—	—

SECONDARY outcome

Timeframe: Week 4 (24 h post dose)

Population: Intensive PK Summary Population: Intensive PK Summary Population comprised of participants with evaluable GSK2336805 PK parameters at Week 4. Only participants available at the indicated time point were assessed (represented by n=X, X in category titles).

Blood samples for PK analysis of GSK2336805 was obtained on Week 4+1 day at predose and at 1, 2, 4, 7, 24 hours post-dose.

Outcome measures

Outcome measures
Measure	GSK2336805 40 mg, Genotype 1 HCV n=11 Participants Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, Genotype 1 HCV n=10 Participants Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, Genotype 1 HCV Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, Genotype 4 HCV Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Maximum Plasma Concentration (Cmax) and Concentration at the End of the Dosing Interval (Ctau) of GSK2336805 at Week 4 Cmax, n=11, 10	335.35 ng/mL Geometric Coefficient of Variation 69.4	618.75 ng/mL Geometric Coefficient of Variation 46.1	—	—
Maximum Plasma Concentration (Cmax) and Concentration at the End of the Dosing Interval (Ctau) of GSK2336805 at Week 4 Ctau, n=11, 10	31.37 ng/mL Geometric Coefficient of Variation 135.9	49.31 ng/mL Geometric Coefficient of Variation 97.6	—	—

SECONDARY outcome

Timeframe: Week 4 (24 h post dose)

Population: Intensive PK Summary Population

Blood samples for PK analysis of GSK2336805 was obtained on Week 4+1 day at predose and at 1, 2, 4, 7, 24 hours postdose.

Outcome measures

Outcome measures
Measure	GSK2336805 40 mg, Genotype 1 HCV n=11 Participants Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, Genotype 1 HCV n=10 Participants Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, Genotype 1 HCV Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, Genotype 4 HCV Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Time of Maximal Plasma Concentration (Tmax) of GSK2336805 at Week 4	2 hour Interval 1.0 to 4.0	2 hour Interval 1.0 to 7.0	—	—

SECONDARY outcome

Timeframe: Week 4 (24 h post dose)

Population: Intensive PK Summary Population

Blood samples for PK analysis of GSK2336805 was obtained on Week 4+1 day at predose and at 1, 2, 4, 7 and 24 hours postdose.

Outcome measures

Outcome measures
Measure	GSK2336805 40 mg, Genotype 1 HCV n=11 Participants Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, Genotype 1 HCV n=10 Participants Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, Genotype 1 HCV Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, Genotype 4 HCV Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) at Week 4	2733.34 hournanogram per milliliter(hrng/mL) Geometric Coefficient of Variation 82	4948.23 hournanogram per milliliter(hrng/mL) Geometric Coefficient of Variation 66.3	—	—

SECONDARY outcome

Timeframe: Week 4 (24 h post dose)

Population: Intensive PK Summary Population

Blood samples for PK analysis of GSK2336805 was obtained on Week 4+1 day at predose and at 1, 2, 4, 7 and 24 hours postdose. CL/F was calculated as dose divided by AUC(0-tau).

Outcome measures

Outcome measures
Measure	GSK2336805 40 mg, Genotype 1 HCV n=11 Participants Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken in 2 divided doses with food.	GSK2336805 60 mg, Genotype 1 HCV n=10 Participants Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	Telaprevir, Genotype 1 HCV Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.	GSK2336805 60 mg, Genotype 4 HCV Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was \<75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was \>=75 kg) taken orally in 2 divided doses with food.
Apparent Clearance (CL/F) at Week 4	14.63 Liter per hour (L/hr) Geometric Coefficient of Variation 82	12.13 Liter per hour (L/hr) Geometric Coefficient of Variation 66.3	—	—

SECONDARY outcome

Timeframe: Week 4 (24 h post dose)

Population: Intensive PK Summary Population

Blood samples for PK analysis of GSK2336805 was obtained on Week 4+1 day at predose and at 1, 2, 4, 7 and 24 hours postdose. Vz/F was calculated as dose divided by (AUC\[0-tau\] lambda z) where lambda z is the terminal phase rate constant.